ArticleDiscover oncology2024
Improved lymph node detection in minimally invasive radical surgery for colorectal cancer using nanocarbon tracer.
Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The clinical value of nanocarbon suspension and methylene blue in sentinel lymphatic tracing and pathologic fine sorting of penile cancer: a multicentre prospective study.Annals of medicine · 2025Trial
- Efficacy of Nano-Carbon Tracing Versus Indocyanine Green in Lymph Node Detection for Minimally Invasive Colorectal Resection.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the influencing factors of lymph node detection after minimally invasive radical surgery in patients with colorectal cancer (CRC) and the application value of carbon nanoparticle tracing. A total of 120 patients with CRC who underwent minimally invasive radical surgery were included. They were divided into groups according to whether they were grouped by carbon nano-tracers, and the baseline data were matched by propensity score method. Univariate and multivariate methods were used to evaluate lymph nodes and positive lymph nodes after minimally invasive radical surgery. The number of detected independent factors. After propensity score matching, there were 37 patients in the tracer group and the non-tracer group; there was no significant difference in baseline data between the two groups; the number of positive lymph nodes detected in the tracer group was significantly higher than that in the non-tracer group. The results of univariate analysis showed that gender, lesion location, maximum tumor diameter, and whether to perform nanocarbon tracing were all related to the number of lymph nodes detected after minimally invasive radical surgery. Nanocarbon tracing was an independent influencing factor for the number of lymph nodes detected after minimally invasive radical surgery. Pathological type, T stage, histopathological grade, nerve invasion, and whether or not with cancer nodules were all related to the number of positive lymph nodes detected after minimally invasive radical surgery; multivariate analysis showed that T stage, pathological Histological grade, vascular invasion, and cancer nodules were all independent influencing factors for the number of positive lymph nodes detected after minimally invasive radical surgery. The number of lymph nodes detected in patients with CRC after minimally invasive radical surgery is closely related to the location of the lesion and whether carbon nanoparticle tracing is performed; those with T2-4 stage, histological grade 3-4, combined with vascular invasion and cancer nodules are more likely to Positive lymph nodes were detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.